Psychiatric and cognitive disorders in Parkinson's disease

Current Opinion in Psychiatry

Volumn 17, Issue 3, 2004, Pages 197-202

  Nilsson, Flemming Mørkeberg ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AMAGER HOSPITAL   (Denmark)

Author keywords

Affective disorder; Anxiety; Dementia; Parkinson's disease; Psychosis

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; ZIPRASIDONE;

COGNITIVE DEFECT; COMORBIDITY; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; MENTAL DISEASE; MOTOR CONTROL; MOTOR DYSFUNCTION; PARKINSON DISEASE; PSYCHOSIS; REVIEW;

EID: 2342643430     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200405000-00008     Document Type: Review

References (82)

1. Bédard MA, Agid Y, Chouinard S, et al. Mental and behavioral dysfunction in movement disorders. Totowa, NJ: Humana Press; 2003.
2. Starkstein SE, Merello M. Psychiatric and cognitive disorders in Parkinson's disease. Cambridge, UK: Cambridge University Press; 2002.
3. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8:383-392.
4. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000; 15:669-677.
5. Cubo E, Rojo A, Ramos S, et al. The importance of educational and psychological factors in Parkinson's disease quality of life. Eur J Neurol 2002; 9:589-593.
6. Marinus J, Visser M, Martinez-Martin P, et al. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol 2003; 58:81-67.
7. Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Quality of life measurements in patients with Parkinson's disease: a community-based study. Eur J Neurol 1998; 5:443-450.
8. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69:308-312.
9. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8:193-197. An evaluation of diagnostic practice in 101 PD patients. Depression, anxiety, and fatigue were not recognized in about half of the patients.
10. Rabinstein AA, Shulman LM. Management of behavioral and psychiatric problems in Parkinson's disease. Parkinsonism Relat Disord 2000; 7:41-50.
11. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely, and Jones; 1817.
12. Anguenot A, Loll PY, Neau JP, et al. Depression and Parkinson's disease: study of a series of 135 Parkinson's patients [in French]. Can J Neurol Sci 2002; 29:139-148.
13. Brandstadter D, Oertel WH. Depression in Parkinson's disease. Adv Neurol 2003; 91:371-381. Extensive review of comorbidity issues and evaluation of treatment studies.
14. Burn DJ. Depression in Parkinson's disease. Eur J Neurol 2002; 9 (Suppl 3):44-54.
15. Nilsson FM, Kessing LV, Sorensen TM, et al. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand 2002; 106:202-211. Large-scale register-based epidemiological study.
16. Oertel WH, Hoglinger GU, Caraceni T, et al. Depression in Parkinson's disease: an update. Adv Neurol 2001; 88:373-383.
17. Zesiewicz TA, Hauser RA. Depression in Parkinson's disease. Curr Psychiatry Rep 2002; 4:69-73.
18. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149:443-454.
19. Leentjens AF, Lousberg R, Verhey FR. Markers for depression in Parkinson's disease. Acta Psychiatr Scand 2002; 106:196-201. In a logistic regression model, risk factors for depression in PD patients were investigated to find disease-specific markers. It was established that risk factors for idiopathic depression were also markers for depression in PD, the most important marker being a positive family history of depression. 'Right-sided onset' was the only PD specific risk factor able to improve the fit of the model.
20. Aarsland D, Cummings JL. Depression in Parkinson's disease. Acta Psychiatr Scand 2002; 106:181-162.
21. Okun MS, Watts RL. Depression associated with Parkinson's disease: clinical features and treatment. Neurology 2002; 58:S63-S70.
22. Tom T, Cummings JL. Depression in Parkinson's disease: pharmacological characteristics and treatment. Drugs Aging 1998; 12:55-74.
23. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001; 104:380-386.
24. Schuurman AG, van den Akker M, Ensinck KT, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002; 58:1501-1504. A retrospective cohort study design based in general practice. A strong positive association was found between depression and incidence of PD.
25. Gonera EG, van't Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997; 12:871-876.
26. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10:399-406. An interesting new approach.
27. Brusa L, Bassi A, Stefani A, et al. Pramipexole in comparison to L-dopa: a neuropsychological study. J Neural Transm 2003; 110:373-380.
28. Chung TH, Deane KH, Ghazi-Noori S, et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord 2003; 10:59-65.
29. Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18:524-530.
30. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002; 59:1427-1429.
31. Linazasoro G. Subthalamic deep brain stimulation for advanced Parkinson's disease: all that glitters is not gold. J Neurol Neurosurg Psychiatry 2003; 74:827.
32. Vingerhoets FJ, Villemure JG, Temperli P, et al. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 2002; 58:396-401.
33. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72:701-707. Improvement in parkinsonian motor disability induced by subthalamic stimulation is not necessarily accompanied by improvement in psychic function and quality of life. This has been debated in recent years. In this well conducted study PD patients were successfully treated for motor disability and levodopa reduction and the behavioural symptoms were evaluated. Presurgical psychiatric examination and psychological evaluation were recommended.
34. Kulisevsky J, Berthier ML, Gironell A, et al. Mania following deep brain stimulation for Parkinson's disease. Neurology 2002; 59:1421-1424.
35. Daniele A, Albanese A, Conterino MF, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74:175-182.
36. Ostergaard K, Sunde N, Dupont E. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 2002; 17:693-700.
37. Mayberg HS, Lozano AM. Penfield revisited? Understanding and modifying behavior by deep brain stimulation for PD. Neurology 2002; 59:1298-1299. An editorial overview of deep brain stimulation with references to the most recent literature.
38. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67:492-496.
39. Pluck GC, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73:636-642.
40. Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002; 17:1099-1105.
41. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65:115-138.
42. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48:938-942.
43. Lennox BR, Lennox GG. Mind and movement: the neuropsychiatry of movement disorders. J Neurol Neurosurg Psychiatry 2002; 72 (Suppl 1):I28-I31.
44. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15:201-211.
45. Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol 2002; 15:156-170.
46. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26:643-659. Extensive review with comparison of latest published papers on atypical antipsychotic drugs.
47. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002; 23 (Suppl 2):S89-S90.
48. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18:510-514.
49. Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003; 26:8-11.
50. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45:1305-1308.
51. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53:538-542.
52. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60:387-392. Eight-year prospective follow-up study of the original Norwegian population-based study of PD. The 8-year prevalence of dementia in a PD population was 78.2%. Of the original study population 37% had died or refused to participate at follow-up. This is accounted for. An elegant use of a control group makes it possible to estimate some risk factors - hallucinations at baseline and akinetic-dominant PD.
53. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56:730-736.
54. Aarsland D, Cumminga JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001; 18:184-191.
55. Kaasinen V, Rinne JO. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev 2002; 28:785-793. Functional imaging is becoming more and more important. This study compares cognitive decline in normal aging and PD by studying changes in the dopamine system. Cautious conclusions are made.
56. Carbon M, Marie RM. Functional imaging of cognition in Parkinson's disease. Curr Opin Neurol 2003; 16:475-480.
57. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59:1714-1720.
58. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74:852-856. An important contribution to the discussion on DLB and PD with dementia from the Queens Square Brain Bank.
59. Girotti F, Soliveri P. Cognitive and behavioral disturbances in Parkinson's disease. Neurol Sci 2003; 24 (Suppl 1):S30-S31.
60. Hardy J. The relationship between Lewy body disease, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci 2003; 991:167-170. A discussion of the nosological entities of diagnosing DLB, PD, and Alzheimer's disease. It is suggested that there is a continuum between these disease processes. In research this is important - in daily clinics it is a practical problem to handle in the best possible way for the patients!
61. Richard IH, Papka M, Rubio A, Kurlan R. Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002; 17:1161-1165. An important discussion on the one- versus two-disease problem.
62. Sulkava R. Differential diagnosis between early Parkinson's disease and dementia with Lewy bodies. Adv Neurol 2003; 91:411-413.
63. McKeith IG, Burn DJ, Ballard CG, et al. Dementia with Lewy bodies. Semin Clin Neuropsychiatry 2003; 8:46-57.
64. Londos E, Passant U, Risberg J, et al. Contributions of other brain pathologies in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002; 13:130-148.
65. Mendez MF, Cummings JL. Dementia: a clinical approach. Philadelphia, PA: Butterworth & Heinemann; 2003. Third edition of the comprehensive standard book on dementia and its various causes.
66. Almeida OP, Burton EJ, McKeith I, et al. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 16:57-63.
67. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002; 59:1724-1728.
68. Ballard C, O'Brien J, Morris CM, et al. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16:499-503.
69. Helmes E, Bowler JV, Merakey H, et al. Rates of cognitive decline in Alzheimer's disease and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2003; 15:67-71.
70. Locascio JJ, Corkin S, Growdon JH. Relation between clinical characteristics of Parkinson's disease and cognitive decline. J Clin Exp Neuropsychol 2003; 25:94-109.
71. Stern Y, Tang MX, Jacobs DM, et al. Prospective comparative study of the evolution of probable Alzheimer's disease and Parkinson's disease dementia. J Int Neuropsychol Soc 1998; 4:279-264.
72. McKeith I, del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036.
73. Weinstock M, Gorodetsky E, Poltyrev T, et al. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's dsease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:555-561.
74. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72:708-712.
75. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18:258-264.
76. Dautzenberg PL, Wouters CJ, Oudejans I, Samson MM. Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease. Int J Geriatr Psychiatry 2003; 18:555-556.
77. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003; 16:184-188.
78. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantsmine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18:937-941.
79. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2:229-237.
80. Kaufer DI. Pharmacologic therapy of dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2002; 15:224-232.
81. Khotianov N, Singh R, Singh S. Lewy body dementia: case report and discussion. J Am Board Fam Pract 2002; 15:50-54.
82. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT. Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry 2003; 18:879-886.